Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26753582 | 0.87 | CCR5 (0.32) | KDM1ACCR5 | |
| SCHEMBL20028833 | 0.84 | NCF1 (0.35) | KDM1AACHE | |
| SCHEMBL20028304 | 0.84 | NCF1 (0.35) | KDM1AACHE | |
| SCHEMBL19477247 | 0.84 | NCF1 (0.35) | KDM1AACHE | |
| SCHEMBL26743216 | 0.83 | HRH3 (0.45) | KDM1AHRH3CYP2D6ACHESLC6A4 | |
| SCHEMBL25492962 | 0.82 | NCF1 (0.41) | KDM1AHRH3ACHE | |
| SCHEMBL26746739 | 0.82 | HRH3 (0.35) | KDM1AHRH3ACHEHTR2AHTR2C | |
| SCHEMBL29324792 | 0.82 | CYP2D6 (0.38) | KDM1AHRH3CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL29323908 | 0.82 | GNAO1 (0.38) | KDM1AHRH3CYP2D6ACHESLC6A4 | |
| SCHEMBL26744662 | 0.82 | NPY1R (0.37) | KDM1AHRH3CYP2D6SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | KDM1A 1195/4885HRH3 4026/4885CYP2D6 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.